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Background: The ﬁbrinogen γ’ variant (γ’) has both antithrombotic and prothrombotic properties when com-
pared to normal ﬁbrinogen. It may therefore be of relevance in intracerebral hemorrhage and intraventricular
extension of the bleeding.
Objective: To study the role of γ’ in intracerebral hemorrhage, and in intraventricular extension of the hem-
orrhage.
Patients/Methods:We performed a case-control study in 156 controls and 55 patients with intracerebral hem-
orrhage, with and without intraventricular extension. Levels of ﬁbrinogen γ’ and the γ’/total ﬁbrinogen ratio
were measured in all participants.
Results: Levels of γ’ were increased in patients with intracerebral hemorrhage when compared with controls
(0.40 vs 0.32 g/l, pb0.001). The γ’/total ﬁbrinogen ratio was similar in patients and controls (0.092 vs 0.096
p=0.42). There was evidence for an unfavorable outcome in patients with ﬁbrinogen levels in the highest
tertile compared with the lowest tertile (OR 4.0, 95%CI 1.1-15.2), and a nonsigniﬁcant trend toward unfavor-
able outcome with higher levels of γ’ (p-value for trend=0.06).
Conclusions: Our study shows that absolute levels of ﬁbrinogen γ’ are increased in patients with intracerebral
hemorrhage, but relative levels are similar in patients and controls, suggesting that the absolute rise in γ’ is
an acute phase response.
© 2011 Elsevier Ltd. Open access under the Elsevier OA license.Introduction
Fibrinogen is one of the central proteins in hemostasis, and several
isoforms are present in the blood. One of these isoforms is ﬁbrinogen
γ’ (γ’), which contains an altered γ chain that is present in 8 to 15% of
ﬁbrinogen molecules [1]. Fibrinogen γ’ is produced after alternative
mRNA processing of the γ chain gene product [2,3]. It has antithrom-
botic properties such as a binding site for thrombin [4] and a
disrupted binding site for platelet integrin αIIBβ3 [5], as well as a
high-afﬁnity binding site for factor XIII:B, which is considered
prothrombotic.
Intracerebral hemorrhage (ICH), resulting from rupture of blood
vessels in the brain, is a severe neurologic disorder leading to a high
rate of mortality and disability [6]. Hemostasis plays an important
role in the pathophysiology of hemorrhagic disorders, such as ICH,
and plays a role in hematoma growth [6]. Larger hematomas areibonucleic acid; ICH, intracere-
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vier OA license.associated with extension of the bleeding into the brain ventricles
(intraventricular extension, IVE) [7]. IVE is associated with an unfa-
vorable prognosis, resulting in a higher mortality [8].
In several cardiovascular disorders, such as myocardial infarction
and ischemic stroke, a pathogenic role of γ’ has been suggested but
not yet proven [9,10]. The role of γ’ in hemorrhagic disorders such
as ICH has, however, not yet been studied. We therefore aimed to de-
termine the association between γ’ levels and the γ’/total ﬁbrinogen
ratio and occurrence of ICH, and with intraventricular extension.
Methods
We performed a case-control study in 55 consecutive patients ad-
mitted to our hospital with non-traumatic intracerebral hemorrhage
between July 2006 and July 2009, and 156 age- and sex matched
stroke-free controls. Participants had no history of coagulation disor-
ders. All individuals participated in the Erasmus Stroke Study (ESS), a
hospital-based registry of patients with cerebrovascular disorders
treated at our hospital. The ESS also includes population-based con-
trols, mostly friends and spouses of patients, but no family. All partic-
ipants provided written informed consent. The institutional Medical
Ethics Committee approved the study.
Upon admission, all patients underwent a plain brain CT scan to
conﬁrm the diagnosis and to determine the presence or absence of
Table 1
Levels of total ﬁbrinogen, ﬁbrinogen γ’ and γ’/total ﬁbrinogen ratio in patients and controls.
Patients Controls
All N=55 No IVE N=47 IVE present N=8 N=156 P value* P value† P value‡ P value§
Total ﬁbrinogen (g/l) 4.41 (1.21) 4.41 (1.23) 4.40 (1.13) 3.37 (0.72) b0.001 0.95 b0.001 b0.001
Fibrinogen γ’ (g/l) 0.40 (0.14) 0.38 (0.14) 0.51 (0.13) 0.32 (0.13) b0.001 0.02 0.01 b0.001
γ’/total ﬁbrinogen ratio 0.092 (0.031) 0.087 (0.032) 0.119 (0.032) 0.096 (0.028) 0.42 0.01 0.08 0.03
Presented are means (SD). All analyses are adjusted for age and sex. *P value between all patients and controls; †P value between patients with and without IVE; ‡P value between
patients without IVE and controls; §P value between patients with IVE and controls.
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was evaluated at discharge by means of the modiﬁed Rankin Scale
(mRS) [11], which is a score for handicap and disability ranging
from 0 (no symptoms) to 6 (death). At a score of 2 patients have dis-
abilities interfering with activities but are still able to live completely
independent; at a score of 3 patients are dependent for activities of
daily living. Unfavorable functional outcome was deﬁned as mRSN2,
signifying loss of independency.
Citrated blood was drawn 3–6 days after admission and centri-
fuged at 1700 g for 15 minutes. Citrated plasma was frozen at
−80 °C within 2 hours from collection and stored until analysis.Laboratory analyses
Total ﬁbrinogen levels were measured according to von Clauss on
a fully-automated coagulation analyzer (Sysmex CA-1500 system,
Siemens Healthcare Diagnostics, Breda, the Netherlands). Fibrinogen
γ’ antigen levels were measured with an enzyme-linked immunosor-
bent assay as described previously [12] using anti-γ’ ﬁbrinogen anti-
bodies for catching and HRP-labeled rabbit anti-ﬁbrinogen antibodies
for tagging.Statistical analysis
Apart from ﬁbrinogen γ’ levels we also determined the γ’/total ﬁ-
brinogen ratio, to adjust for total ﬁbrinogen levels, which are known
to increase as results of an acute phase reactions [13]. Differences in
γ’ levels and γ’/total ﬁbrinogen ratio between patients and controls
and within patient subgroups were assessed by means of multiple lin-
ear regression, adjusted for age and sex. The relation between γ’
levels and the γ’/total ﬁbrinogen ratio and functional outcome was
assessed using logistic regression and expressed as odds ratio (OR)
per tertile increase in ﬁbrinogen level, the lowest tertile being the ref-
erence category. All statistical analyses were performed using SPSS
17.0 for Windows (SPSS Inc., Chicago, Illinois). A probability value
b0.05 was considered signiﬁcant.Table 2
Risk of unfavorable functional outcome (mRS N2) and levels of ﬁbrinogen and ﬁbrinogen γ
Tertiles
1 2
Fibrinogen
Distribution b3.8 g/l 3.8 –
All patients 1.00 (ref) 1.56
Only patients without IVE 1.00 (ref) 1.35
Fibrinogen γ’
Distribution b0.33 g/l 0.33
All patients 1.00 (ref) 5.60
Only patients without IVE 1.00 (ref) 6.24
γ’/total ﬁbrinogen ratio
Distribution b0.078 0.078
All patients 1.00 (ref) 0.80
Only patients without IVE 1.00 (ref) 0.83
Shown are OR (95%CI).Results
Median age was 63 years in patients and 60 years in controls (dif-
ference not signiﬁcant), 55% of patients and 49% of controls were men
(not signiﬁcant). Of all patients, 8 (15%) had intraventricular exten-
sion of the hemorrhage.
Total ﬁbrinogen and γ’ were signiﬁcantly higher in patients than
in controls (Table 1). Table 1 also shows levels in patients with and
without intraventricular extension of the hemorrhage. We found no
difference in the γ’/total ﬁbrinogen ratio between patients and con-
trols. However, the subgroup of patients with IVE had a signiﬁcantly
higher γ’/total ﬁbrinogen ratio than controls and patients without
IVE.
The median modiﬁed Rankin Scale score at discharge was 2 (inter-
quartile range 2–4). Patients with ﬁbrinogen levels in the highest ter-
tile had a signiﬁcantly higher probability of unfavorable outcome,
compared with patients in the lowest tertile. There were also signs
of a linear relationship (p-value for trend over tertiles 0.12,
Table 2). Levels of ﬁbrinogen γ’ seemed to be higher in patients
with unfavorable outcome, but not statistically signiﬁcant. These
risks were not attenuated when patients with IVE were left out of
the analysis.Discussion
In this case-control study, we found that levels of ﬁbrinogen γ’
were strongly elevated in patients with intracerebral hemorrhage as
compared to control persons. In the total patient group, the ﬁbrino-
gen γ’/total ﬁbrinogen ratio was similar to controls, but subgroup an-
alyses revealed an increased γ’/total ﬁbrinogen ratio in patients with
intraventricular extension of the hemorrhage, while in patients with-
out IVE, this γ’/total ﬁbrinogen ratio was somewhat lower, although
not statistically signiﬁcant, than in controls.
Strengths of our study are the novelty of studying ﬁbrinogen γ’ in
intracerebral hemorrhage, and the availability of a functional out-
come measure. A methodological concern of our study is the small
number of patients. Intracerebral hemorrhage, a rare disorder when’ and the γ’/total ﬁbrinogen ratio, in tertiles of the distribution.
3 p-trend
4.4 g/l N4.4 g/l
(0.41-5.95) 4.00 (1.05-15.21) 0.12
(0.32-5.71) 2.62 (0.66-10.48) 0.39
– 0.44 g/l N0.44 g/l
(1.36-23.06) 2.80 (0.71-11.10) 0.06
(1.44-27.06) 2.60 (0.56-12.02) 0.05
– 0.101 N0.101
(0.21-3.00) 1.72 (0.47-6.32) 0.50
(0.21-3.35) 2.25 (0.54-9.45) 0.38
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die before arriving in the hospital or within hours from admission
[6,14]. This makes any study of patients with intracerebral hemor-
rhage, including our own, vulnerable to bias as many patients are
not included. A second point is the case control design of the study,
which makes it difﬁcult to study causal relationships between ﬁbrin-
ogen γ’ and ICH.
Although the anti- and prothrombotic properties of γ’ have been
studied quite extensively, most clinical research in this ﬁeld has
been done in thromboembolic disorders such as venous thrombosis,
myocardial infarction and ischemic stroke [10,12,15–17]. No studies
have yet been performed focusing on the antithrombotic properties
of γ’ in relation to hemorrhage.
The γ’ chain has a binding site for thrombin, with both antithrom-
botic or prothrombotic consequences, which have been subject of dis-
cussion [4,18,19]. Despite this, thrombin binding to the γ’ chain
overall seems to be antithrombotic, reducing the free thrombin con-
tent and inhibiting thrombin-mediated platelet activation [20,21].
Also, the binding of thrombin leads to a selective inhibition of the in-
trinsic coagulation pathway [19]. An additional antithrombotic prop-
erty of γ’ is the decreased binding to platelet integrin αIIBβ3 by the γ’
chain, leading to a diminished platelet aggregation activity [22].
Given the antithrombotic properties of γ’, one might hypothesize
that γ’ might also affect the risk and outcome of (intracerebral) hem-
orrhage. Thus far, no studies have been done on this particular
subject.
In our study we found that γ’ levels were indeed increased in pa-
tients with intracerebral hemorrhage. However, due to the case con-
trol design we can't rule out that this ﬁnding is the result of an
acute phase response in ICH patients [9].
Previous studies have shown a stronger acute phase response in
patients with blood in the intraventricular or subarachnoid space
[23–25]. The relevance of intraventricular blood may play a role in
our ﬁnding that relative ﬁbrinogen γ’ levels seem to increase signiﬁ-
cantly only in patients with extension of bleeding into the ventricles.
However, in our study the presence or absence of IVE did not affect
total ﬁbrinogen levels. The reason for this discrepancy remains un-
known, but it has been hypothesized that the direct contact between
blood and cerebrospinal ﬂuid might play a role [23].
Our ﬁnding that patients with high levels of total ﬁbrinogen had a
signiﬁcantly higher chance of unfavorable outcome is in line with
ﬁndings from previous studies [26,27]. The prognostic value of ﬁbrin-
ogen γ’ in patients with ICH is still unclear. The risk estimates we
found for unfavorable outcome in higher tertiles of ﬁbrinogen γ’,
was present in all patients, also after removing patients with IVE
from the analysis. Larger studies are required to explore the prognos-
tic value of ﬁbrinogen γ’ in patients with ICH.
Any hemorrhage leads to consumption of coagulation factors; for
intracerebral hemorrhage, literature is very limited with very little
knowledge on consumption in this category of patients. The volume
of the hemorrhage is usually small, varying depending on the method
used, between 30–50 ml [28,29]. Considering the small size of the
hemorrhage, systemic consumption of coagulation factors will be
minimal and not affect the results that we measured in our study.
In conclusion, the level of ﬁbrinogen γ’ is increased in patients
with intracerebral hemorrhage compared with controls; however,
the ratio of γ’/total ﬁbrinogen ratio is similar, suggesting that the
rise in ﬁbrinogen γ’ may reﬂect an acute phase response.
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